Blue Jet Healthcare Limited released its Business Responsibility and Sustainability Report (BRSR) for FY26 on August 18, 2026. The Navi Mumbai-based manufacturer of contrast media, high-intensity sweeteners, and pharmaceutical intermediaries highlighted significant progress in its environmental sustainability metrics during the reporting period.

The company reported a substantial shift in its energy mix, with renewable energy consumption rising by 28% year-on-year. Total renewable energy usage reached 40,836.79 GJ in FY26, up from 26,321.38 GJ in FY25. This increase was driven by the commissioning of a 5.625 MW solar power plant and the installation of a 3.2 MW windmill. Consequently, approximately 57% of the company’s total energy requirements are now met through renewable sources.

Environmental Performance

The expansion of renewable capacity contributed to a measurable decline in carbon emissions. Scope 1 and Scope 2 greenhouse gas emissions decreased to 32,138.47 tCO2e in FY26, down from 34,885.47 tCO2e in FY25. The company also implemented boiler efficiency monitoring and automatic coal combustion control systems, which resulted in a 5–8% reduction in specific emissions including CO2, NOx, and SOx.

Water management remains a critical focus for the chemical manufacturing entity. Blue Jet Healthcare operates a Zero Liquid Discharge (ZLD) system across its facilities. During FY26, the company treated and reused 48,827 KL of water through its Effluent Treatment Plant (ETP) and Reverse Osmosis (RO) systems. Treated water is recycled for utility applications such as cooling towers and boilers, reducing freshwater dependency.

Social and Governance Highlights

On the social front, the company maintained a workforce of 508 employees and 73 workers at the end of FY26. Women represented 37.5% of the Board of Directors and 50% of Key Managerial Personnel. The company reported zero Lost Time Injury Frequency Rate (LTIFR) and zero fatalities for employees and workers during the financial year.

Blue Jet Healthcare obtained reasonable assurance on its BRSR Core KPIs from TÜV India Private Limited. The company also initiated Scope 3 emissions accounting for selected categories in FY26, marking its first year of reporting under this framework. Exports accounted for approximately 90% of total turnover, with operations serving over 50 countries including the USA, Norway, and various European nations.

Blue Jet Healthcare Limited reported a full-year revenue of ₹9,473 million for the financial year ended March 31, 2026 (FY26), marking an 8% decline from the previous year. The company’s Profit After Tax (PAT) fell 18.8% to ₹2,478 million, driven primarily by customer inventory destocking in its Pharma Intermediates and API segment and pricing pressures in the artificial sweeteners business.

Despite the revenue contraction, the company maintained robust profitability metrics. EBITDA stood at ₹2,941 million, representing a margin of 31%, while the PAT margin remained strong at 26%. The Managing Director noted that Q1 saw exceptional momentum with revenue surging 118% year-on-year to ₹355 million, but this was followed by a sharp moderation in Q2 and Q3 as customers normalized their inventory levels. Q4 marked a recovery, with revenue rising 22% quarter-on-quarter to ₹235 million.

Financial Highlights

*Figures derived from disclosed percentage changes or prior year disclosures where available.

Strategic Investments and Capital Raise

The company successfully raised ₹8,000 million through the allotment of 15,810,276 equity shares under a Qualified Institutional Placement (QIP) on July 9, 2026. This capital infusion strengthens the balance sheet, which closed FY26 with approximately ₹350 million in liquid financial assets and zero debt. Operating cash flow for the year stood at ₹334 million.

Blue Jet Healthcare is actively expanding its manufacturing footprint. The company entered into an agreement to purchase a 102.48-acre industrial land parcel in Andhra Pradesh for ₹435.02 million to set up a new manufacturing facility. Additionally, the backward integration project at its Mahad facility is progressing well, aimed at reducing dependence on external raw material sources. A new R&D centre in Hyderabad, focusing on GLP-1 intermediates and peptide chemistry, has also been secured on lease.

Dividend and Corporate Governance

The Board of Directors recommended a final dividend of ₹1.20 per equity share for FY26, subject to shareholder approval at the 58th Annual General Meeting (AGM). The AGM is scheduled to be held on September 21, 2026, via Video Conferencing/Other Audio-Visual Means (OAVM).

Key corporate actions include the re-appointment of Mr. Naresh Suryakant Shah as Whole-Time Director and the re-appointment of M/s. KKC & Associates LLP as Statutory Auditors for a second term of five years. The Board also approved the re-appointment of Executive Chairman Mr. Akshay Bansarilal Arora and Managing Director Mr. Shiven Akshay Arora for further terms commencing April 13, 2027.

What the Numbers Show

While top-line revenue contracted by 8%, the company’s EBITDA margin held steady at 31%, indicating that cost structures remained resilient despite volume headwinds in key segments. The significant drop in PAT (18.8%) relative to the revenue decline suggests a disproportionate impact from specific segment underperformance, particularly in Pharma Intermediates and APIs, rather than broad-based operational inefficiencies. The debt-free status and substantial cash reserves provide a strong buffer for ongoing capex commitments, including the ₹1,000 crore planned investment in the Vizag greenfield facility.